ReviewSeminars in nuclear medicine2020
FDG PET/CT for Assessment of Immune Therapy: Opportunities and Understanding Pitfalls.
Review in Seminars in nuclear medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- The Future of Cancer Diagnosis, Treatment and Surveillance: A Systemic Review on Immunotherapy and Immuno-PET Radiotracers.Molecules (Basel, Switzerland) · 2021Pooled it
- Radiopharmaceuticals in Malignant Melanoma: A Comprehensive Review of Diagnostic, Therapeutic, and Immune-Related Applications by PET/CT, SPECT/CT, and PET/MRI.Diagnostics (Basel, Switzerland) · 2025Review
- Approaches to Imaging Immune Activation Using PET.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Review
- [European journal of nuclear medicine and molecular imaging · 2025Article
- IsCancers · 2024Review
- ImmunoPET provides a novel way to visualize the CD103EJNMMI research · 2024Review
- Case report: Incidental MALT lymphoma of the left adrenal gland mimicking a metastatic spread within durvalumab maintenance treatment in inoperable stage III non-small cell lung cancer.Frontiers in oncology · 2024Article
- Innovative applications and future trends of multiparametric PET in the assessment of immunotherapy efficacy.Frontiers in oncology · 2024Review
- Positron emission tomography molecular imaging to monitor anti-tumor systemic response for immune checkpoint inhibitor therapy.European journal of nuclear medicine and molecular imaging · 2023Review
- Diagnostic impact ofClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022Article
- Glucose-Thymidine Ratio as a Metabolism Index UsingInternational journal of molecular sciences · 2022Article
- Clinical Impact of Dual Time PointCancers · 2022Article
- F18-FDG PET/CT imaging early predicts pathologic complete response to induction chemoimmunotherapy of locally advanced head and neck cancer: preliminary single-center analysis of the checkrad-cd8 trial.Annals of nuclear medicine · 2022Article
- PET-CT in Clinical Adult Oncology-VI. Primary Cutaneous Cancer, Sarcomas and Neuroendocrine Tumors.Cancers · 2022Review
- 2-deoxy-2[18F]fluoro-D-glucose positron emission tomography-computed tomography in rheumatological diseases.Rheumatology (Oxford, England) · 2022Review
- F-18 Fluoro-2-Deoxyglucose Positron Emission Tomography (PET)/Computed Tomography (CT) Imaging in Melanoma: Normal Variants, Pitfalls, and Artifacts.Frontiers in nuclear medicine · 2022Review
- Frontiers and hotspots ofFrontiers in oncology · 2022Article
- Article
- Image intensity histograms as imaging biomarkers: application to immune-related colitis.Biomedical physics & engineering express · 2021Article
- NSCLC Biomarkers to Predict Response to Immunotherapy with Checkpoint Inhibitors (ICI): From the Cells to In Vivo Images.Cancers · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Immune checkpoint blockade has demonstrated the ability to modulate the immune system to produce durable responses in a wide range of cancers and has significantly impacted the standard of care. However, many cancer patients still do not respond to immune checkpoint blockade or have a limited duration of antitumor responses. Moreover, immune-related adverse events caused by immune checkpoint blockade can be severe and debilitating for some patients, limiting continuation of therapy and resulting in severe autoimmune conditions. Standard-of-care conventional anatomic imaging modalities and tumor response criteria have limitations to adequately assess tumor responses, especially early in the course of therapy, for risk-adapted clinical management to inform care of patients treated with immunotherapy. Molecular imaging with position emission tomography (PET) provides a noninvasive functional biomarker of tumor response, and of immune activation, for patients on immune-based therapies to help address these needs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.